Ask AI
ProCE Banner Activity

CE

From Target to Tolerability: Nurse-Led Strategies for Optimizing Bispecific Antibody Therapy in Multiple Myeloma

Video

Enhance your care for patients with multiple myeloma (MM) by hearing from experts on their integration of bispecific antibodies into practice, such as personalized treatment plans and adverse symptom management, in this on demand webcast.

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: May 29, 2026

Expiration: November 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Johnson & Johnson.

Johnson & Johnson

Target Audience

This activity has been designed to meet the educational needs of community oncology nurses, nurse practitioners, and other healthcare professionals caring for patients with multiple myeloma.

Program Learning Goal

The activity aims to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and other healthcare professionals in educating and caring for patients with multiple myeloma receiving bispecific antibody therapy. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with multiple myeloma

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific antibodies

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma

  • Educate patients with myeloma and their caregivers on how to identify and mitigate risk and thereby improve outcomes

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Charise Gleason, MSN, NP-C, AOCNP, has no relevant financial relationships to disclose.

Tiffany Richards, PhD, ANP-BC, AOCNP: consultant/advisor/speaker: Bristol Myers Squibb, Pfizer, Regeneron, Sanofi.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 29, 2026, through November 28, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

  • Care of the Pediatric Hematology and Oncology Patient (CPHON) - 0.75*
  • Foundations of Transplant/HSCT and Cellular Therapy (TCTCN) - 0.75*
  • Oncologic Emergencies (OCN, CPHON, AOCNP) - 0.5*
  • Oncology Nursing Practice (OCN) - 0.75*
  • Pediatric Hematology Oncology Nursing Practice (CPHON) - 0.75*
  • Professional Practice/Performance (TCTCN, AOCNP, ROCN) - 0.25*
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) - 0.5*
  • Treatment (AOCNP, CBCN, CPHON, OCN, ROCN) - 1.0*

Total Points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.